Clinical diagnosis, viral PCR, and antibiotic utilization in community-acquired pneumonia

American Journal of Therapeutics

Volumn 23, Issue 3, 2016, Pages e766-e772

  Afzal, Zeeshan ^a   Minard, Charles G ^a   Stager, Charles E ^a   Yu, Victor L ^b   Musher, Daniel M ^a,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

antibiotic stewardship; CAP; viral PCR

Indexed keywords

ANTIBIOTIC AGENT; COTRIMOXAZOLE; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PNEUMONIA; BLOOD CULTURE; COMMUNITY ACQUIRED PNEUMONIA; GENERAL PRACTITIONER; HUMAN; LEGIONELLA; MAJOR CLINICAL STUDY; NONHUMAN; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESPIRATORY VIRUS; SPUTUM CULTURE; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; VIRUS DETECTION; VIRUS PNEUMONIA; COMMUNITY-ACQUIRED INFECTIONS; DRUG UTILIZATION; HUMAN RESPIRATORY SYNCYTIAL VIRUS; ISOLATION AND PURIFICATION; MICROBIOLOGY; PNEUMOCYSTIS CARINII; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCYSTIS; PNEUMONIA, VIRAL; PROSPECTIVE STUDY; TEXAS; VIROLOGY;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG UTILIZATION; HUMANS; LEGIONELLA; PNEUMOCYSTIS CARINII; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCYSTIS; PNEUMONIA, VIRAL; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RESPIRATORY SYNCYTIAL VIRUSES; STREPTOCOCCUS PNEUMONIAE; TEXAS;

EID: 84890355424     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0000000000000018     Document Type: Article

References (35)

1. Bonafede MM, Suaya JA, Wilson KL, et al. Incidence and cost of CAP in a large working-age population. Am J Manag Care. 2012; 18: 380-387
2. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of communityacquired pneumonia in adults. Clin Infect Dis. 2007; 44: S27-72
3. Niederman MS, Bass JB Jr, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis. 1993; 148: 1418-1426
4. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community acquired pneumonia in adults. Clin Infect Dis. 2000; 31: 347-382
5. Moran GJ, Rothman RE, Volturo GA. Emergency management of community-acquired bacterial pneumonia: what is new since the 2007 Infectious Diseases Society of America/American Thoracic Society guidelines. Am J Emerg Med. 2013; 31: 602-612
6. Yu VL. A clinical solution to antimicrobial resistance in community-acquired pneumonia: narrowing the spectrum of antimicrobial therapy: comment on Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy. Arch Intern Med. 2011; 171: 172-173
7. Waterer GW, Rello J, Wunderink RG. Management of community-acquired pneumonia in adults. Am J Respir Crit Care Med. 2011; 183: 157-164
8. Stralin K. Usefulness of aetiological tests for guiding antibiotic therapy in community-acquired pneumonia. Int J Antimicrob Agents. 2008; 31: 3-11
9. Avdic E, Cushinotto LA, Hughes AH, et al. Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia. Clin Infect Dis. 2012; 54: 1581-1587
10. Halm EA, Teirstein AS. Clinical practice. Management of community-acquired pneumonia. N Engl J Med. 2002; 347: 2039-45
11. Musher DM. Streptococcus pneumoniae. In: Mandell GL, B JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Churchill Livingstone; 2010: 2623-2642
12. Niederman MS. Principles of appropriate antibiotic use. Int J Antimicrob Agents. 2005; 26: S170-175
13. Roumie CL, Halasa NB, Grijalva CG, et al. Trends in antibiotic prescribing for adults in the United States-1995 to 2002. J Gen Intern Med. 2005; 20: 697-702
14. Musher DM, Roig IL, Cazares G, et al. Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study. J Infect. 2013; 67: 11-18
15. Vergis EN, Yu VL. New directions for future studies of community-acquired pneumonia: optimizing impact on patient care. Eur J Clin Microbiol Infect Dis. 1999; 18: 847-851
16. Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax. 2001; 56: 296-301
17. Bartlett JG. Diagnostic tests for agents of communityacquired pneumonia. Clin Infect Dis. 2011; 52: S296-304
18. San Pedro GS, Campbell GD Jr. Limitations of diagnostic testing in the initial management of patients with community-acquired pneumonia. Semin Respir Infect. 1997; 12: 300-307
19. Van Der Eerden MM, Vlaspolder F, de Graaff CS, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax. 2005; 60: 672-678
20. Sanyal S, Smith PR, Saha AC, et al. Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia. Am J Respir Crit Care Med. 1999; 160: 346-348
21. Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis. 2010; 50: 202-209
22. Oosterheert JJ, van Loon AM, Schuurman R, et al. Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection. Clin Infect Dis. 2005; 41: 1438-1444
23. Nussenblatt V, Avdic E, Cosgrove S. What is the role of antimicrobial stewardship in improving outcomes of patients with CAP?. Infect Dis Clin North Am. 2013; 27: 211-228
24. Kanwar M, Brar N, Khatib R, et al. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. Chest. 2007; 131: 1865-1869
25. Mertz D, Koller M, Haller, et al. Outcomes of early switching from intravenous to oral antibiotics on medical wards. J Antimicrob Chemother. 2009; 64: 188-199
26. Omidvari K, de Boisblanc BP, Karam G, et al. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med. 1998; 92: 1032-1039
27. Polgreen PM, Chen YY, Cavanaugh JE, et al. An outbreak of severe Clostridium-difficile-associated diseases possibility related to inappropriate antimicrobial therapy for community-acquired pneumonia. Infect Control Hosp Epidemiol. 2007; 28: 212-214
28. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31: 431-455
29. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002; 346: 334-339
30. Rosón B, Carratalà J, Fernández-Sabé N, et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med. 2004; 164: 502-508
31. Seppälä H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med. 1997; 337: 441-446
32. Chen DK, McGeer A, de Azavedo JC, et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med. 1999; 34: 233-239
33. Scalera NM, File TM Jr. Determining the duration of therapy for patients with community-acquired pneumonia. Curr Infect Dis Rep. 2013; 15: 191-195
34. El Moussaoui R, de Borgie CA, van Den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomized double blind study. BMJ. 2006; 332: 1355
35. Musher DM, Bebko SP, Roig IL. Serum procalcitonin level, viral polymerase chain reaction analysis, and lower respiratory tract infection. J Infect Dis. 2014; 209, in press